NCT02333591View on ClinicalTrials.gov

Effect of Intact GLP-1 (7-36) and GLP-1 Metabolite (9-36) on Coronary and Peripheral Vascular Function in Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Coronary Microvascular Dysfunction
Interventions
DRUG

GlucagonLikePeptide-1 (7-36)

Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.

DRUG

GlucagonLikePeptide-1 (9-36)

Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.

DRUG

Saline

Infused intravenously for 2,5 hours.

Trial Locations (1)

2400

Department of Research in Endocrinology, Bispebjerg University Hospital, Copenhagen

All Listed Sponsors
collaborator

Hvidovre University Hospital

OTHER

lead

Mette Zander

OTHER

NCT02333591 - Effect of Intact GLP-1 (7-36) and GLP-1 Metabolite (9-36) on Coronary and Peripheral Vascular Function in Adults | Biotech Hunter | Biotech Hunter